This statistic shows select widely-used specialty therapeutic drugs in the United States regarding their net price change between 2017 a d 2019. The best-selling drug worldwide - Humira (adalimumab) - had a net price growth of 16 percent within two years. Price increases of drugs often appear without being based on new clinical evidence and are therefore hotly discussed.

ABSTRACT Price regulation aims to ensure sustainability of pharmaceutical care. Aiming to critically discuss the regulation of pharmaceutical prices in Brazil, we elaborated an essay based on document analysis (2000-2017) of the pharmaceutical economic regulation found at the Medication Regulation Chamber (CMED), journals, theses, and publications of the Legislature and pharmaceutical industry. For 15 years, Act no. 10.742/2003 has established a price ceiling model, comprising maximum prices for medicines and annual readjustments according to a formula defined in law. Model, implementation and formula have all been criticized. The formula links adjustments to the IPCA (general inflation index), adding indexes for production costs, competition, and productivity. The longevity of the model, without regular realignment of the ceiling to actual market prices, as recommended in specialized literature, generates price ceilings detached from reality, which deepen information asymmetries and may support abusive price increases in the future. Prioritization of market efficiency over reduction of information asymmetry in the regulatory model has reduced the strength of consumers in the debate. The current regulatory model has advanced in relation to previous liberalized pricing policies, but further improvement depends on the appropriation of the theme and increasing participation of consumers and health professionals in the regulatory process.

Between 2019 and 2023, spending for Eliquis under Medicare increased by 31 percent annually on average per dosage unit. This statistic illustrates the average annual Medicare spending growth among select top-selling drugs in the United States, for the time range 2019-2023.

In 2022, the average U.S. net price of product portfolios of large pharmaceutical manufacturers decreased by *** percent from the previous year. In the same year, the average increase of the U.S. list price compared to the previous year was four percent. This statistic illusrates the change in U.S. list and net pharmaceutical product prices from 2017 to 2022.

United States CPI U: AW: Medical Care: CO: Medicinal Drugs (MD) data was reported at 1.797 % in 2017. This records an increase from the previous number of 1.792 % for 2016. United States CPI U: AW: Medical Care: CO: Medicinal Drugs (MD) data is updated yearly, averaging 1.665 % from Dec 2010 (Median) to 2017, with 8 observations. The data reached an all-time high of 1.797 % in 2017 and a record low of 1.554 % in 2010. United States CPI U: AW: Medical Care: CO: Medicinal Drugs (MD) data remains active status in CEIC and is reported by Bureau of Labor Statistics. The data is categorized under Global Database’s USA – Table US.I011: Consumer Price Index: Urban: Weights (Annual).

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Antacids (PCU325412325412D113) from Dec 2009 to May 2017 about pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

The Centers for Medicare and Medicaid Services estimate that prescription drug expenditure in the United States will reach around 460 billion U.S. dollars in 2024. This amount includes only retail drug spending, excluding nonretail. Estimations of drug spending can vary by investigating organization. For the U.S., among the most relevant drug spending calculations are provided by CMS, ASPE (Assistant Secretary for Planning and Evaluation), and pharmaceutical market researcher IQVIA. High drug prices in the U.S.The United States is the country with the highest total drug spending, and also with the highest per capita pharmaceuticals spending among developed countries. This is mostly connected to higher drug prices in the United States. For example, the price for the blockbuster drug Humira was almost three times higher in the United States than in Germany in 2017. But whereas in other countries, governments more or less directly control drug prices, the U.S. leaves drug pricing to market competition. As a consequence, the U.S. market is the most profitable for pharmaceutical companies. Where the money is spentNearly half of all Americans have taken at least one prescription medicine within the preceding month. The therapeutic areas where spending is the highest are ‘traditionally’ to be found among antidiabetics, oncologics, autoimmune, and respiratory diseases. Based on number of prescriptions filled, antihypertensives, pain reliever, and mental health drugs are the leading classes.

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Calcium Channel Blockers (PCU3254123254127114) from Dec 2009 to May 2017 about pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Emollients and Protectives, Including Burn Remedies (PCU325412325412G211) from Dec 2009 to May 2017 about pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

United States PCE: 2017p: saar: NG: Others: PM: Prescription Drugs data was reported at 533.290 USD bn in Mar 2025. This records an increase from the previous number of 520.241 USD bn for Feb 2025. United States PCE: 2017p: saar: NG: Others: PM: Prescription Drugs data is updated monthly, averaging 367.495 USD bn from Jan 2007 (Median) to Mar 2025, with 219 observations. The data reached an all-time high of 533.290 USD bn in Mar 2025 and a record low of 339.729 USD bn in Oct 2012. United States PCE: 2017p: saar: NG: Others: PM: Prescription Drugs data remains active status in CEIC and is reported by Bureau of Economic Analysis. The data is categorized under Global Database’s United States – Table US.A089: NIPA 2023: Personal Consumption Expenditure: Chain Linked 2017 Price: saar.

India Pharmaceutical: Drugs Price Control Order: Monitoring and Enforcement: Referred for Overcharging data was reported at 930.000 Unit in 2017. This records an increase from the previous number of 613.000 Unit for 2016. India Pharmaceutical: Drugs Price Control Order: Monitoring and Enforcement: Referred for Overcharging data is updated yearly, averaging 302.500 Unit from Mar 2008 (Median) to 2017, with 10 observations. The data reached an all-time high of 1,020.000 Unit in 2015 and a record low of 152.000 Unit in 2012. India Pharmaceutical: Drugs Price Control Order: Monitoring and Enforcement: Referred for Overcharging data remains active status in CEIC and is reported by Department of Pharmaceuticals. The data is categorized under India Premium Database’s Pharmaceutical Sector – Table IN.RTG004: Pharmaceutical: Monitoring and Enforcement: Drugs Price Control Order.

These are graphical summaries comparing price change against inflation over the cumulative period from 2017 to 2020. We took the 2017 prices for all the drug formulations, calculated based on inflation what the price would be (using both the general inflation rate and healthcare inflation rate) and plotted the actual prices on the same graph. We performed this for both the copay prices and the AWP, using inflation data based off the US Bureau of Labor Statistics to perform our calculations.

ObjectiveSince 2016, the Chinese government has been regularly implementing the National Reimbursement Drug List Negotiation (NRDLN) to improve the accessibility of drugs. In the second round of NRDLN in July 2017, 18 anticancer drugs were included. This study analyzed the impact of the NRDLN on the accessibility of these 18 anticancer drugs in China.MethodsNational hospital procurement data were collected from 2015 to 2019. As measurements of drug accessibility, monthly average of drug availability or defined daily dose cost (DDDc) was calculated. Interrupted time series (ITS) analysis was employed to evaluate the impact of NRDLN on drug accessibility. Multilevel growth curve models were estimated for different drug categories, regions or levels of hospitals.ResultsThe overall availability of 18 anticancer drugs increased from about 10.5% in 2015 to slightly over 30% in 2019. The average DDDc dropped from 527.93 CNY in 2015 to 401.87 CNY in 2019, with a reduction of 23.88%. The implementation of NRDLN was associated with higher availability and lower costs for all 18 anticancer drugs. We found an increasing level in monthly drug availability (β2 = 2.1126), which ascended more sharply after the implementation of NRDLN (β3 = 0.3656). There was a decreasing level in DDDc before July 2017 (β2 = −108.7213), together with a significant decline in the slope associated with the implementation of NRDLN (β3 = −4.8332). Compared to Traditional Chinese Medicines, the availability of Western Medicines was higher and increased at a higher rate (β3 = 0.4165 vs. 0.1108). Drug availability experienced a larger instant and slope increase in western China compared to other regions, and in secondary hospitals than tertiary hospitals. Nevertheless, regional and hospital-level difference in the effect of NRDLN on DDDc were less evident.ConclusionThe implementation of NRDLN improves the availability and reduces the cost of some anticancer drugs in China. It contributes to promoting accessibility of anticancer drugs, as well as relieving regional or hospital-level disparities. However, there are still challenges to benefit more patients sufficiently and equally. It requires more policy efforts and collaborative policy combination.

This statistic shows the annual price growth rate of pharmaceutical products in Italy in selected years from 2000 to 2017. According to data, in 2017 the price of pharmaceutical products increased by *** percent as compared to the previous year.

In 2020, the average retail price of Chinese patent drugs sold in conventional pharmacies in China almost reached ** yuan per unit, representing a two percent increase from the previous year. Although the price of Chinese patent drugs increased continuously in the past few years, they remained generally affordable to most patients, with the exceptions of high-end medicines such as Angong Niuhuang Wan and Pien Tze Huang.

Brazil Pharmaceutical: Cost & Expenses data was reported at 58,815,040.000 BRL th in 2017. This records an increase from the previous number of 57,082,736.000 BRL th for 2016. Brazil Pharmaceutical: Cost & Expenses data is updated yearly, averaging 40,101,903.000 BRL th from Dec 2007 (Median) to 2017, with 11 observations. The data reached an all-time high of 58,815,040.000 BRL th in 2017 and a record low of 24,877,473.000 BRL th in 2007. Brazil Pharmaceutical: Cost & Expenses data remains active status in CEIC and is reported by Brazilian Institute of Geography and Statistics. The data is categorized under Brazil Premium Database’s Chemical and Petrochemical Sector – Table BR.RHE012: Chemical and Petrochemical Financial Data: Pharmaceutical.

INPC: Ytd: Rio de Janeiro: Health and Personal Care: Pharmaceutical and Optical: Pharmaceuticals: Antidiabetic data was reported at 3.610 % in Mar 2025. This records an increase from the previous number of 0.320 % for Feb 2025. INPC: Ytd: Rio de Janeiro: Health and Personal Care: Pharmaceutical and Optical: Pharmaceuticals: Antidiabetic data is updated monthly, averaging 5.030 % from Jan 2020 (Median) to Mar 2025, with 63 observations. The data reached an all-time high of 18.340 % in Oct 2022 and a record low of -3.340 % in May 2020. INPC: Ytd: Rio de Janeiro: Health and Personal Care: Pharmaceutical and Optical: Pharmaceuticals: Antidiabetic data remains active status in CEIC and is reported by Brazilian Institute of Geography and Statistics. The data is categorized under Brazil Premium Database’s Inflation – Table BR.IC048: Consumer Price Index - INPC: POF: 2017-2018: Dec1993=100: Year-to-Date: by Municipality: Rio de Janeiro: Rio de Janeiro.

Brazil INPC: Year to Date: Health and Personal Care: Pharmaceutical and Optical: Pharmaceuticals: Antidiabetic data was reported at 0.980 % in Mar 2025. This records an increase from the previous number of 0.710 % for Feb 2025. Brazil INPC: Year to Date: Health and Personal Care: Pharmaceutical and Optical: Pharmaceuticals: Antidiabetic data is updated monthly, averaging 4.070 % from Jan 2020 (Median) to Mar 2025, with 63 observations. The data reached an all-time high of 14.280 % in Aug 2022 and a record low of -5.180 % in May 2020. Brazil INPC: Year to Date: Health and Personal Care: Pharmaceutical and Optical: Pharmaceuticals: Antidiabetic data remains active status in CEIC and is reported by Brazilian Institute of Geography and Statistics. The data is categorized under Brazil Premium Database’s Inflation – Table BR.IB044: Consumer Price Index - INPC: POF 2017-2018: Dec1993=100: Year-to-Date.

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Anticoagulants, Hemostatics, and Digitalis Preparations (PCU3254123254127111) from Jun 1981 to May 2017 about pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.